Following successful percutaneous coronary intervention for acute ST-elevation myocardial infarction ... 6 months after bone-marrow-derived cell transfer (n = 30) We have recently reassessed ...

Ischemic heart disease is a common consequence of coronary artery disease (CAD), which is primarily driven by atherosclerosis, a chronic inflammatory ...

These findings open new doors for macrophage-based therapies, which could enhance myocardial repair without relying on exogenous stem cell transplantation. Read the full story here.

The therapeutic approach was safe, but the study did not meet its primary efficacy outcome using the six-minute walking test.

A preview ceremony was held Sunday for the Osaka Healthcare Pavilion to be run by the prefecture and city of Osaka at the ...

CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, named its new Board of Directors led by co-founder Jérôme Koch, in line with recent bridge financing organized ...